Enterprise Value
-67.22M
Cash
183.9M
Avg Qtr Burn
-31.11M
Short % of Float
16.72%
Insider Ownership
48.58%
Institutional Own.
42.76%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Posoleucel Details BK virus, Kidney transplantation | Phase 2 Update | |
Posoleucel Details Epstein-Barr virus, Human herpesvirus 6, BK virus, Adenovirus, Cytomegalovirus | Failed Discontinued | |
Posoleucel Details Virus-associated hemorrhagic cystitis , Adenovirus | Failed Discontinued | |
ALVR106 Details Respiratory syncytial virus, Influenza, Human metapneumovirus, Parainfluenza virus | Failed Discontinued | |
ALVR109 Details COVID-19 | Failed Discontinued |